Nicholas Investment Partners LP Invests $7.33 Million in Vera Therapeutics, Inc. $VERA

Nicholas Investment Partners LP bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 144,810 shares of the company’s stock, valued at approximately $7,333,000. Nicholas Investment Partners LP owned approximately 0.21% of Vera Therapeutics as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Vera Therapeutics in the fourth quarter valued at about $46,000. Quantbot Technologies LP acquired a new stake in Vera Therapeutics in the second quarter valued at about $51,000. Tower Research Capital LLC TRC boosted its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after buying an additional 639 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $34.26 on Friday. The stock has a market cap of $2.46 billion, a P/E ratio of -6.18 and a beta of 0.93. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average is $37.02 and its 200-day moving average is $41.38. Vera Therapeutics, Inc. has a 1-year low of $19.07 and a 1-year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the company posted ($0.81) earnings per share. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Analyst Ratings Changes

VERA has been the topic of several research analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research note on Friday, May 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $10,362,498.20. The trade was a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.